First Event of Infection by HIV-1 of Uterine Vaginal Tissue

HIV Infection of the Uterine Vaginal Tissues Clinical Trial

Official title:

Inhibition by the Antibody, First Event of Infection by HIV-1 of Uterine Vaginal Tissue

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02481622
• Other study ID #: 6197
• Status: Recruiting
• Phase: N/A
• First received: June 7, 2015
• Last updated: April 21, 2017
• Start date: November 2015
• Est. completion date: November 2019

Study information

• Verified date: November 2015
• Source: University Hospital, Strasbourg, France
• Contact: Jeanine OHL, MD
• Phone: 33 3 3 88 11 67 68
• Email: jeanine.ohl[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This non-interventional study aims to characterize the cells infected with HIV over time in different types of vagino-uterine tissue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: November 2019
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Patients whose age =50 years and =18 years

• Patients for which surgery like laparoscopy or hysterectomy is necessary as part of a benign pathology.

Exclusion Criteria:

• Patients under 18 years

Related Conditions & MeSH terms

• Communicable Diseases
• HIV Infection of the Uterine Vaginal Tissues
• HIV Infections
• Infection

Locations

Country	Name	City	State
France	INSERM U1109 - Institut de Virologie 3, rue Koeberlé - 67000 Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	identification of the first HIV-infected cells by a histological analysis		after surgery, up to 3 weks